Literature DB >> 23910428

Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty.

Giuseppe De Luca1, Arnoud W J van't Hof, Kurt Huber, C Michael Gibson, Francesco Bellandi, Hans-Richard Arntz, Mauro Maioli, Marko Noc, Simona Zorman, Uwe Zeymer, H Mesquita Gabriel, Ayse Emre, Donald Cutlip, Tomasz Rakowski, Maryann Gyongyosi, Dariusz Dudek.   

Abstract

Hypertension is a well-known risk factor for atherosclerosis. However, data on the impact of hypertension in patients with ST elevation myocardial infarction (STEMI) are inconsistent and mainly related to studies performed in the thrombolytic era, with very few data on patients undergoing primary angioplasty. The aim of the present study was to evaluate the impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with STEMI undergoing primary percutaneous coronary intervention. Our population is represented by 1,662 patients undergoing primary angioplasty for STEMI included in the Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty database. Myocardial perfusion was evaluated by myocardial blush grade and ST segment resolution. Follow-up data were collected within 1 year after primary angioplasty. Hypertension was observed in 700 patients (42.1%). Hypertension was associated with more advanced age (p <0.001), female gender (p <0.001), diabetes (p <0.001), hypercholesterolemia (p <0.001), previous revascularization (p <0.001), anterior myocardial infarction (p = 0.006), longer ischemia time (p = 0.03), more extensive coronary artery disease (p = 0.002), more often treated with abciximab (p <0.001), and less often smokers (p <0.001). Hypertension was associated with impaired postprocedural myocardial blush grade 2 to 3 (68.2% vs 74.2%, p = 0.019) and complete ST segment resolution (51.7% vs 61.1%, p = 0.001). By a mean follow-up of 206 ± 158 days, 70 patients (4.3%) had died. Hypertension was associated with a greater mortality (6.2% vs 2.9%, hazard ratio 2.31, 95% confidence interval 1.42 to 3.73, p <0.001), confirmed after correction for baseline confounding factors (hazard ratio 1.82, 95% confidence interval 1.03 to 3.22, p <0.001). In conclusion, this study showed that among patients with STEMI undergoing primary angioplasty, hypertension is associated with impaired reperfusion and independently predicts 1-year mortality.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23910428     DOI: 10.1016/j.amjcard.2013.05.053

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

2.  Hemodynamic effects of topical lidocaine on the laryngoscope blade and trachea during endotracheal intubation: a prospective, double-blind, randomized study.

Authors:  Sue-Young Lee; Jeong Jin Min; Hyun Joo Kim; Deok Man Hong; Hyun-Jung Kim; Hee-Pyoung Park
Journal:  J Anesth       Date:  2014-03-12       Impact factor: 2.078

3.  The impact of diabetes mellitus and hypertension on clinical outcomes in a population of Iranian patients who underwent percutaneous coronary intervention: A retrospective cohort study.

Authors:  Mohammad Javad Zibaeenezhad; Seyyed Saeed Mohammadi; Mehrab Sayadi; Soorena Khorshidi; Ehsan Bahramali; Iman Razeghian-Jahromi
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-25       Impact factor: 3.738

Review 4.  Spontaneous and procedural plaque embolisation in native coronary arteries: pathophysiology, diagnosis, and prevention.

Authors:  Giovanni Luigi De Maria; Niket Patel; George Kassimis; Adrian P Banning
Journal:  Scientifica (Cairo)       Date:  2013-12-19

5.  Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction.

Authors:  Sebastian J Reinstadler; Thomas Stiermaier; Charlotte Eitel; Mohammed Saad; Bernhard Metzler; Suzanne de Waha; Georg Fuernau; Steffen Desch; Holger Thiele; Ingo Eitel
Journal:  J Cardiovasc Magn Reson       Date:  2016-11-11       Impact factor: 5.364

6.  Impact of Admission Systolic Blood Pressure and Antecedent Hypertension on Short-Term Outcomes After ST-Segment Elevation Myocardial Infarction: Strobe-Compliant Article.

Authors:  Wenfang Ma; Yan Liang; Jun Zhu; Yanmin Yang; Huiqiong Tan; Litian Yu; Xin Gao; Guangxun Feng; Jiandong Li
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

Review 7.  Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of 100 Studies.

Authors:  Pravesh Kumar Bundhun; Zi Jia Wu; Meng-Hua Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction.

Authors:  David Carrick; Caroline Haig; Annette M Maznyczka; Jaclyn Carberry; Kenneth Mangion; Nadeem Ahmed; Vannesa Teng Yue May; Margaret McEntegart; Mark C Petrie; Hany Eteiba; Mitchell Lindsay; Stuart Hood; Stuart Watkins; Andrew Davie; Ahmed Mahrous; Ify Mordi; Ian Ford; Aleksandra Radjenovic; Paul Welsh; Naveed Sattar; Kirsty Wetherall; Keith G Oldroyd; Colin Berry
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.